#Clew medical stock software

She also serves on corporate boards of HicuityHealth, and CareConnectMD. Roscoe has held numerous executive and management roles at healthcare and technology companies, including VisionWare Inc., Sybase and New Era of Networks (acquired by Sybase).īarbara has been a member of Clew’s board of directors since 2018. Roscoe joined Microsoft, after the acquisition of Sentillion, where he served as President and led the business to become the industry leader in Healthcare Identity Management.

Prior to Crimson, he was General Manager of Microsoft’s Healthcare Solutions Group. healthcare market, experiencing massive growth in customers and value creation. Roscoe served as the CEO of Crimson, a division of the Advisory Board Company, and led the business to become the de-facto standard healthcare analytics company in the U.S. Roscoe also established high contract value relationships with some of the country’s most respected health systems, including Dignity Health, Sutter Health, HSS, Northwell and Ohio Health. Roscoe was CEO, Co-Founder and Board member of Docent Health where he launched, capitalized and commercialized the business resulting in the company being recognized as one of the most innovative and successful solutions in the growing healthcare CRM/patient engagement segment. 'CLEW's AI-based solution is a huge leap forward in ICU patient care, providing preemptive and potentially life-saving information that enables early intervention, reduces alarm fatigue and can potentially significantly improve clinical outcomes,' stated Professor Craig Lilly, University of Massachusetts Medical School.Prior to joining Clew, Mr Roscoe was CEO of Trinda Health, and was responsible for establishing the company as the industry leader in quality oriented clinical documentation solutions. David Bates, Medical Director of Clinical and Quality Analysis in Information Systems at Mass General Brigham healthcare system and CLEW Advisory Board member. 'AI can be a powerful force for change in healthcare, enabling assessment of time-critical patient information and predictive warning of deterioration that could enable better informed clinical decisions and improved outcomes in the ICU,' said Dr. 'We are proud to have received this landmark FDA clearance and deliver a first-of-its-kind product for the industry, giving healthcare providers the critical data that they need to prevent life-threatening situations,' said Gal Salomon, CLEW CEO. The data is analyzed in near real-time to present calculated insights and notifications for dedicated AI models and provides a picture of overall unit status. CLEWICU receives patient data from various sources, including Electronic Health Record (EHR) data and medical device data.

#Clew medical stock software

The analytical software product uses AI-based algorithms and machine-learning models trained to identify the likelihood of occurrence of significant clinical events for patients in the intensive care unit (ICU). The system also identifies low-risk patients who are unlikely to deteriorate, thus enabling better ICU resource management and optimization. The system provides notification of clinical deterioration up to eight hours in advance, enabling early evaluation and subsequent intervention for prompt, proactive patient care.

Conducting effective risk evaluation to improve patient identification and subsequent care plans requires the use of advanced tools that can provide comprehensive, predictive data to help medical professionals identify patients whose health conditions are likely to deteriorate, in addition to patients whose conditions are unlikely to deteriorate.ĬLEWICU continuously monitors and categorizes patient risk levels, providing clinicians with physiological insight into a patient's likelihood of future hemodynamic instability. The COVID-19 pandemic has underscored the critical need for quick and accurate decision-making in intensive care units, as ICU capacity has faced unprecedented volumes. The clearance is the FDA's first for such a device, and follows the FDA's Emergency Use Authorization (EUA) for CLEWICU's respiratory deterioration model granted in June 2020, for the predictive screening of COVID-19 and other ICU patients. Food and Drug Administration (FDA) has given 510(k) clearance and authorized the use of 'CLEWICU,' CLEW's artificial intelligence (AI) based ICU solution, to predict hemodynamic instability in adult patients. 3, 2021 /PRNewswire/ - CLEW Medical, a leader in AI-powered predictive analytics, today announced that the U.S. TEL AVIV, Israel and WILMINGTON, Delaware, Feb.